Claims
- 1. A co-crystal of mammalian Glucokinase and a ligand bound to an allosteric site of the Glucokinase, wherein
the co-crystal has unit cell dimensions of:
a and b are from about 79 Å to about 80.2 Å; c is from about 318 Å to about 325 Å; α and β are 90°; and γis 120°; and the co-crystal has P6(5)22 symmetry.
- 2. A crystal of mammalian Glucokinase, wherein
the crystal has unit cell dimensions of:
a and b are from about 79 Å to about 80.2 Å; c is from about 318 Å to about 325 Å; α and β are 90°; and γ is 120°; and the crystal has P6(5)22 symmetry.
- 3. A process for co-crystalizing mammalian Glucokinase and an allosteric ligand of Glucokinase, the process comprising:
providing a buffered, aqueous solution of about 9 to about 22 mg/ml the mammalian Glucokinase; adding a molar excess of the allosteric ligand to the aqueous solution of mammalian Glucokinase; and growing crystals by vapor diffusion using a buffered reservoir solution of about 16% to about 25% PEG, about 0% w/v to about 30% w/v glucose and about 8 to about 10 mM DTT, wherein the PEG has an average molecular weight of about 8,000 to about 10,000.
- 4. The process of claim 3, wherein the step of growing crystals by vapor diffusion comprises:
streaking the buffered, aqueous solution of mammalian Glucokinase with added allosteric ligand on a surface to form an elongated droplet of protein solution, and streaking about an equal amount of the buffered reservoir solution across the elongated droplet of protein solution, forming a combined droplet shaped like the letter ‘X’.
- 5. The compound
Parent Case Info
[0001] This application claims priority of Provisional application Serial No. 60/341,988, filed Dec. 19, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60341988 |
Dec 2001 |
US |